# SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors

Source: https://onco.cc/trials/nct07022002/  
OnCo record `nct07022002` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of SSGJ-705 in advanced solid tumours, run by Shenyang Sunshine Pharmaceutical Co., LTD., now recruiting.

## Summary

SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors is a phase 2 interventional study registered as NCT07022002 by Shenyang Sunshine Pharmaceutical Co., LTD., with 340 participants planned, started 2025-07-30 and due to reach its primary completion in 2026-12-31. Interventions recorded: SSGJ-705, PD-1/L1 inhibitor combined with chemotherapy and SSGJ-705 combined with chemotherapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07022002
- Phase: 2
- Setting: A Phase II Study to Evaluate the Safety and Efficacy of SSGJ-705 Monotherapy and Combination Therapy in Patients With Advanced HER2-Expressing Solid Tumors
- Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.
- Enrolled: 340

## Sources

- ClinicalTrials.gov NCT07022002: https://clinicaltrials.gov/study/NCT07022002

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [SSGJ-705](https://onco.cc/drugs/ssgj-705/)

---
JSON: https://onco.cc/api/v1/entities/nct07022002.json